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Lymphodepletion and infusion of autologous expanded tumour-infiltrating lymphocytes is effective therapy for patients with
malignant melanoma. Antitumour responses are likely to be mediated by HLA class I- and II-restricted immune responses directed at
tumour antigens. We assessed whether the peripheral blood of normal HLA-matched siblings of patients with melanoma could be
used to generate lymphocytes with antimelanoma activity for adoptive immunotherapy after allogeneic blood or marrow
transplantation. Melanoma cell lines were derived from two donors and were used to stimulate the mononuclear cells of three HLA-
identical siblings. CD4
þ clones dominated cultures. Of these, approximately half were directly cytotoxic towards recipient melanoma
cells and secreted interferon-g in response to tumour stimulation. More than half of the noncytotoxic clones also secreted interferon-
g after melanoma stimulation. No CD4
þ clones responded to stimulation with recipient haemopoietic cells. The majority of CD8
þ
clones directly lysed recipient melanoma, but did not persist in long-term culture in vitro. No crossreactivity with recipient
haemopoietic cells was observed. The antigenic target of one CD4
þ clone was determined to be an HLA-DR11-restricted MAGE-3
epitope. Antigenic targets of the remaining clones were not elucidated, but appeared to be restricted through a non-HLA-DR class II
molecule. We conclude that the blood of allogeneic HLA-matched sibling donors contains melanoma-reactive lymphocyte
precursors directed at tumour-associated antigens. Adoptive immunotherapy with unselected or ex vivo-stimulated donor
lymphocytes after allogeneic stem cell transplantation has a rational basis for the treatment of malignant melanoma.
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Allogeneic blood or marrow transplantation is emerging as an
effective treatment in some patients with solid tumours, particu-
larly those with renal cell carcinoma (Childs et al, 1999; Childs,
2000). Other tumours including breast and ovarian cancers and
germ cell tumours may also benefit from this approach (Bay et al,
2000, 2002; Pedrazzoli et al, 2002; Hanel et al, 2003; Donato et al,
2004), which is thought to exert its major antitumour effect via
donor immune cells active against recipient malignancy (known as
the graft-versus-tumour or GVT effect). The GVT effect makes the
use of lymphocytes from HLA-identical donors preferable to the
use of the patient’s own lymphocytes for the purpose of generating
cells for immunotherapy.
Melanoma cells express a variety of tumour antigen types that
could be the target of immune responses. These include the cancer
testis antigens exemplified by the MAGE family as well as
differentiation antigens such as tyrosinase and melan-A/MART-1
that are expressed by normal melanocytes as well as melanoma
cells (Coulie et al, 1993; Boon et al, 1994). T-lymphocytes specific
for tumour antigens can be detected at low frequency in the
circulation of both melanoma sufferers and normal individuals
(Lee et al, 1999; Valmori et al, 2000; Pittet et al, 2001). The use of
blood from HLA-identical donors offers two major advantages.
Patients with melanoma may have deficient immune responses
owing to advanced malignancy itself or to the effects of
chemoradiotherapy. In addition, the expression of polymorphic
tissue antigens by melanoma cells offers additional antigens that
can be targeted by allogeneic lymphocytes.
When autologous melanoma-infiltrating lymphocytes expanded
in vitro are infused into melanoma sufferers following lymphode-
pleting chemotherapy, a 50% rate of objective response has been
observed in patients with metastatic melanoma (Dudley et al, 2002,
2005). Tumour targets have included the products of MAGE, HLA,
tumour suppressor and other polymorphic genes (Robbins et al,
2002; Huang et al, 2004; Zhou et al, 2005). However, the process
of cell generation requires the use of lymphocytes isolated from
tumour biopsies and is labour intensive and impractical for
routine clinical purposes. To take advantage of the additional
alloreactivty provided by polymorphic minor histocompatibility
antigens and to utilise the immunocompetent systems of normal
donors, we generated melanoma cell lines from two patients with
metastatic melanoma and used them to stimulate lymphocytes Revised 5 June 2006; accepted 6 June 2006; published online 4 July 2006
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sfrom the peripheral blood of their HLA-identical siblings. We
aimed to determine the ease with which melanoma-reactive clones
could be generated and to characterise the clones. We intended to
determine the feasibility of infusing in vitro expanded melanoma-
reactive allogeneic lymphocytes following reduced-intensity
lymphodepleting chemotherapy and establishment of allogeneic
haemopoietic chimerism in patients with melanoma.
MATERIALS AND METHODS
Cell lines
Approval from our Institutional Ethics Committee was granted
and informed consent from donors was obtained before collection
of any biological samples. Melanoma samples were obtained from
surgical biopsies of metastatic lesions in two patients WMPG
(tissue type HLA-A1, B44, 49, DRB1 11, 12) and WMMH (tissue
type HLA-A3, 24, B7, 35, DRB1 13, 15). Biopsies of melanoma
lesions from patients were washed in sterile PBS, cut into small
pieces and digested with trypsin-EDTA (Invitrogen, Carlsbad, CA,
USA) until all tumour aggregates were disassociated. The cells
harvested were centrifuged and cultured in RPMI mediaþ10%
FCS at 371C in a humidified atmosphere containing 5% CO2.
Nonadherent cells were discarded and adherent cells were
passaged using trypsin-EDTA. Cell lines had the appearance of
large adherent cells typical of malignant melanoma cells and were
characterised by reverse transcriptase–polymerase chain reaction
(RT–PCR) for melanoma antigens (see Results). The melanoma
lines ET1 and LB33, and the lymphoblastoid cell line (LCL) LG2-
EBV were kindly provided by Professor T Boon (Ludwig Institute
for Cancer Research, Brussels, Belgium). The melanoma lines MD-
TC, OI-TC, GRA and the HLA-DR11þ BOR-EBV were a kind gift
of Dr MP Protti (Scientific Institute H San Raffaele, Milan, Italy).
Me18732 was kindly provided by Dr Parmiani (Istituto Nazionale
dei Tumori, Milan, Italy). Peripheral blood mononuclear cells
(PBMCs) were isolated from patients or their HLA-A-, -B-, -DRB1-
identical donors by Lymphoprep (Nycomed, Oslo, Norway)
gradients. Activated T cells were obtained by cultivation of PBMC,
in the presence of 1mgml
 1 of PHA (Boehringer Mannheim,
Mannheim, Germany) and 100Uml
 1 r-hu-IL-2 (Chiron, Milan,
Italy). B-lymphoblastoid cell lines were derived by transformation
of peripheral blood B-lymphocytes with the B95-8 strain of EBV,
obtained from the Department of Virology, Institute for Clinical
Pathology and Medical Research, Westmead Hospital. Bone
marrow fibroblasts were isolated by adherence from marrow
aspirates and were cultured in RPMIþ10% FCS, passaged at
confluency and reseeded at 10% confluency.
Flow cytometry
Antibodies to human CD3, CD4, CD8, CD13, CD19, CD56, CD80,
CD86, CD62L, interferon-g and IL-4 were purchased from BD
Biosciences (San Jose, CA, USA). W6/32 (anti-HLA class I) was
purchased from Sigma-Aldrich (St Louis, MO, USA). Flow
cytometry was carried out on a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA, USA) and analysed using CellQuest
software. To label intracellular antigens including cytokines, cells
were first fixed by incubation in 4% paraformadehyde. After
washing, cells were incubated in ICPerm (Biosource, Nivelles,
Belgium) and were labelled with primary antibodies and washed in
PBS. If the primary antibody was not conjugated to fluorochromes,
fluorochrome-conjugated secondary antibody was added and cells
were incubated before washing and analysing on the flow cytometer.
In vitro induction of tumour-specific effectors
Autologous mixed lymphocyte tumour cell cultures (MLTCs) were
established as described previously (Van den Eynde et al, 1989)
using irradiated autologous tumour in the presence of 10Uml
 1
IL-2 (Chiron, Milan, Italy) and 5ngml
 1 IL-7 (Genzyme Corp.,
Cambridge, MA, USA). Cultures were maintained in IMDMþ10%
pooled human AB serum supplemented with 0.55mML -arginine,
0.24mML -asparagine and 1.5mML -glutamine, 50Uml
 1 penicillin
and 50mgml
 1 streptomycin. Lymphocytes were stimulated weekly
and tested in cytotoxicity or cytokine release assays after three
stimulations. On day 21, lymphocytes from the culture were cloned
by limiting dilution and maintained in culture as described
previously (Traversari et al, 1989). In brief, lymphocytes from
MLTCs were counted and seeded in 96-well plates at a ratio of
0.3cellswell
 1. To each well, 500 melanoma cells (g-irradiated to
90Gy), 30000 EBV-transformed feeder lymphoblastoid cells
(irradiated to 90Gy) and IL-2 (final concentration 50Uml
 1)
were added in a total culture volume of 200mlwell
 1. Half of the
media and IL-2 were replaced every 3–4 days, and fresh irradiated
melanoma cells and EBV-LCL feeder cells were added weekly as
above. After 3–4 weeks, wells were examined by light microscopy
for outgrowth of lymphocytes. Positive wells were maintained at
10
5cellswell
 1 until expanded sufficiently for testing.
Cytotoxicity assay
The lytic activity of CTLs was tested in a classical chromium
release assay (Gottlieb et al, 1989), in the presence of 30:1 excess
of cold K562 cells. For blocking assays, the effector cells were
preincubated with Ab specific for CD3 (OKT3: Orthoclone, Milan,
Italy), CD4, CD8 or alternatively target cells were preincubated
with anti-MHC class I (W6/32) and anti-HLA-DR (L243) Abs
30min at room temperature. Effector and target cells were added
in 96-well microplates at a fixed E:T ratio to evaluate the lytic
activity as
51Cr release after 4h.
Cytokine secretion assay
Responder cells (1 10
5) at day 5 after stimulation and stimulator
cells (3 10
5) were mixed in 150ml of IMDM 10% human serum
supplemented with 25Uml
 1 IL-2. After 24h at 371C, 100mlo f
supernatant were harvested, and interferon-g concentration was
measured using an interferon-g ELISA kit (BD Biosciences
Pharmingen, San Diego, CA, USA) according to the manufacturer’s
recommendations. Blocking experiments were performed as
described above.
RESULTS
Characterisation of melanoma cell lines
Cell lines WMPG and WMMH grew as adherent cells with the
typical morphological appearance of melanoma cells. By PCR,
WMPG was shown to express MAGE-2, MAGE-3, MAGE-6,
Melan-A, tyrosinase and gp100, whereas WMMH expressed
MAGE-2, MAGE-3, tyrosinase and Melan-A (Figure 1). Both
WMPG and WMMH expressed high levels of HLA class I and II,
ICAM-1 and LFA-3 (Figure 2). However, neither cell line expressed
B7.1 or B7.2, the principal costimulatory molecules required for
the activation of naı ¨ve T cells (Figure 2). Additionally, neither cell
line expressed cell surface antigens of T, B or natural killer origin
(data not shown).
Generation and characterisation of T-cell clones
Mixed lymphocyte tumour cell cultures were established using
WMPG melanoma cells and effectors from his HLA-identical
sibling, and from WMMH and effectors from each of two HLA-
identical siblings. After limiting dilution cloning, a total of 49
lymphocyte clones was obtained from 1560 seeded wells. Only two
out of a total of 49 clones were CD8
þ, the remainder being CD4
þ.
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þ T-cell clones for further study, MLTCs were
sorted into 499% pure CD4
þ and CD8
þ fractions and CD8
þ
T cells were then cloned by limiting dilution. From a total of
960 seeded wells, 47 CD4
þ and 65 CD8
þ clones were obtained
(Table 1). The phenotype of clones was verified periodically
throughout this study. The CD8
þ clones expanded during the
limiting dilution process, but none was able to persist and expand
in culture for more than 2 months after limiting dilution despite
coculture with OKT3 or irradiated allogeneic PBMC from healthy
donors or EBV-transformed feeder cells (LG2-EBV). This limited
their functional characterisation. On the other hand, a number of
CD4
þ T-cell clones were able to survive and expand for greater
than 4 months in culture, enabling their further characterisation in
subsequent experiments.
For a number of CD8
þ T-cell clones, cytotoxicity against
recipient melanoma cells was demonstrated in
51Cr-release
cytotoxicity assays. Data from representative clones are shown in
Figure 3A. Clones QB10 and QF10 were generated by limiting
dilution from CD8
þ-sorted MLTC of the WMPG donor/stimulator
pair. Clone KP8S4 was derived by limiting dilution from CD8
þ-
sorted MLTC of the WMMH donor/stimulator pair. Clones QB10
and QF10 killed recipient melanoma WMPG cells but did not show
cytotoxicity against LG2-EBV feeder cells nor against PHA blasts
derived from the originator of the WMPG line, suggesting that
clones QB10 and QF10 recognised an antigen expressed by
melanoma rather than a minor histocompatibility antigen
expressed by tumour cells. This pattern of cytotoxicity was
observed in 38 out of 45 CD8
þ T-cell clones raised from the
donor against WMPG. Seven out of 45 CD8
þ clones showed no
cytotoxicity against either WMPG or EBV feeder cells. As shown in
Figure 3, KP8S4 killed recipient melanoma WMMH but not LG2-
EBV feeder cells nor EBV-transformed cells from the originator of
the WMMH line, suggesting that KP8S4 also recognised an antigen
expressed by WMMH melanoma but not a minor histocompat-
ibility antigen expressed by donor MH. Only two CD8
þ T-cell
clones derived from WMMH-stimulated cultures (including
KP8S4) could be expanded for testing. As the aim of the study
was only to analyse the characteristics of clones generated from
HLA-identical siblings, no attempt was made to expand clones to
numbers that might be required for therapeutic purposes.
In contrast to CD8
þ clones, most CD4
þ T-cell clones were able
to survive and expand in culture, enabling their further
characterisation. Recognition of WMPG by the lymphocytes was
assessed in
51Cr-release cytotoxicity assays. Results from three
representative clones are shown in Figure 3B. CD4
þ clones DB5
and MC5 killed the recipient melanoma cell line WMPG
specifically and not recipient PHA blasts or the LG2-EBV feeder
cell line. However, another clone JC8 failed to lyse the original
WMPG. Of the 14 CD4
þ clones characterised, four clones
displayed cytotoxicity patterns similar to clones DB5 and MC5.
Another three clones killed WMPG, but cytotoxicity assays were
not performed against PHA blasts owing to the clones dying in
culture. The remaining seven CD4
þ clones did not kill WMPG.
A total of 25 CD4
þ T-cell clones were derived from the two
HLA-identical siblings of the WMMH line. These clones were
tested against WMMH targets in
51Cr-release cytotoxicity assays
(Figure 4A). Two patterns of cytotoxicity were observed. Half of
the CD4
þ clones derived exhibited cytotoxicity directly against
recipient melanoma cells without killing a WMMH-derived EBV
cell line, implying the clones did not recognise a minor
histocompatibility antigen. The remaining clones did not kill the
WMMH melanoma line or EBV-transformed recipient or feeder
cells. All clones that were cytotoxic secreted interferon-g in
response to stimulation with WMMH (Figure 4B). However, four
of the six noncytotoxic clones also released interferon-g in
response to WMMH. No clones tested secreted interferon-g in
response to stimulation with WMMH EBV-transformed cells or
LG2-EBV feeder cells, indicating that no clones recognised minor
histocompatibility antigens expressed by the tumour cells or the
patient’s EBV-transformed cells.
Characterisation of target epitopes of CD4
þ T-cell clones
An attempt was made to identify the antigen(s) recognised by
CD4
þ clones. MAGE-3-derived peptides presented by HLA-DR11
and recognised by CD4
þ T-lymphocytes have previously been
identified (Hahn et al, 1995). To test if any of the clones generated
from the HLA-identical donor of the WMPG patient (that
expressed HLA-DR11) recognised MAGE-3 peptides in association
with HLA-DR11, CD4
þ clones were used as effectors in
cytotoxicity assays against an HLA-DR11þ EBV-LCL engineered
to express MAGE-3. One of seven clones tested (clone PR3) was
cytotoxic against the MAGE-3 transfectant, but not the vector-
only-transfected line (Figure 5A). To validate this result, clone PR3
was tested for its ability to secrete interferon-g in response to
stimulation with six melanoma cell lines (four HLA-DR11þ, two
HLA-DR11 ). Clone PR3 secreted interferon-g in response to
WMPG, the MAGE-3-transfected HLA-DR11þ EBV-transformed
cell line and three of four HLA-DR11þ melanoma cell lines, but
did not secrete interferon-g after stimulation with either of the
HLA-DR11  melanoma lines or after stimulation with an HLA-
DR11þ line (LB33) with low HLA-DR expression (Figure 5B and
EBV-MH WMMH NM182
EBV-AP
MAGE-1
MAGE-2
MAGE-3
MAGE-4
MAGE-6
Melan-A
Tyrosinase
gp100
GAPDH
WMPG NM39
Figure 1 Expression of melanoma antigens by WMPG and WMMH.
Reverse transcriptase–polymerase chain reaction was used to assess
expression of a panel of common melanoma antigens by WMPG and
WMMH. RNA was extracted from WMPG and WMMH, reverse-
transcribed and amplified with primers that anneal to mRNAs of melanoma
antigens. Reverse transcriptase–polymerase chain reaction products of two
EBV-LCL cell lines (EBV-AP and EBV-MH) and two other melanoma cell
lines (NM39 and NM182) were included as negative and positive controls,
respectively. Amplification of GAPDH was shown as loading control. Bands
of sizes corresponding to amplification of mRNAs (instead of genomic
DNA) were shown.
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sdata not shown). The remaining clones failed to respond to either
MAGE-3-transduced or -untransduced HLA-DR11þ EBV lines.
CD4
þ clone APLD2 isolated from one of the HLA-identical donors
of the originator of the WMMH line killed the WMMH cell line but
not EBV-transformed cell lines from the WMMH donor (see
above). An attempt was made to identify the class II restriction
element by inhibiting the cytotoxicity with the anti-HLA-DR
monoclonal antibody L243. The activity of the APLD2 clone was
inhibited by anti-CD3 and anti-CD4 Abs; however, no inhibition of
cytotoxicity or interferon-g release could be obtained implying that
the restriction element must be another (non-HLA-DR) class II
determinant (Figure 6). A donor EBV-transformed cell line was
generated and transfected with retroviral constructs containing
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Figure 2 Expression of HLA, costimulatory molecules and adhesion molecules by WMPG (A) and WMMH (B). Cells were stained with antibodies
specific for (a): HLA class I; (b): HLA class II; (c): B7.1; (d): B7.2; (e): ICAM-1 and (f): LFA-3 and assessed by flow cytometry. Grey lines represent staining with
isotype control antibodies, and black lines staining with the indicated antibodies.
Table 1 Number of CD4+ and CD8+ clones derived from (a) WMPG-
JG donor pair, (b) WMMH-AP donor pair and (c) WMMH-KP donor pair
CD4+
(recognising
stimulator)
CD8+
(recognising
stimulator)
(a) WMPG-JG 22 (7/10/5) 45 (38/6/1)
(b) WMMH-AP 13 (6/1/6) 6 (0/0/6)
(c) WMMH-KP 12 (5/1/6) 14 (2/0/12)
Recognition of stimulator cell was determined either by Cr-release cytotoxicity assay
or interferon-g release as described in Materials and Methods. Numbers in brackets
show the number of clones recognising, not recognising and not tested against the
original stimulator cells, respectively.
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secreted interferon-g against any of the melanoma antigen-
transfected cell lines (data not shown).
DISCUSSION
Infusion of autologous in vitro expanded tumour-infiltrating
lymphocytes into lymphodepleted hosts suffering from melanoma
is associated with high rates of disease response in patients with
advanced disease (Dudley et al, 2005). The use of allogeneic donors
as a source of immune system cells could have benefits, in
particular the recognition of minor histocompatibility antigens on
tumour cells by allogeneic donor lymphocytes and the potential
for improved functional immune responses using cells from
noncompromised healthy donors. In this work, we assessed the
potential for HLA-A-, -B- and -DR-identical sibling donors to act
as a source of melanoma-reactive lymphocytes that could exert a
GVT effect if infused after allogeneic stem cell transplant. Both
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Figure 3 Cytotoxicity of T-cell clones. CD8
þ T-cell clones against recipient melanoma cells. (A) CD8
þ T-cell clones QB10 and QF10 from the WMPG
donor–recipient pair, and clone KP8S4 from the WMMH donor–recipient pair were used as effectors against recipient melanoma cells (solid dots), the
feeder cells LG2-EBV (open circles) and cell lines of recipient origin (PHA-PG for QB10 and QF10, EBV-MH for KP8S4; solid triangles). Error bars represent
95% confidence interval (CI) calculated from triplicates. (B) CD4
þ T-cell clones DB5, MC5 and JC8 were used as effectors in cytotoxicity assays against
WMPG (solid dots), the feeder cells LG2-EBV (open circles) and PHA blasts from WMPG (solid triangles). Error bars represent 95% CIs calculated from
triplicates.
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Figure 4 (A) Cytotoxicity of CD4
þ clones raised from WMMH donors. Clones APLD2, APLD3, APLD4 and KPLD10 were used as effectors against
recipient melanoma (solid dots), recipient-derived EBV-LCL (solid triangles) and the feeder cells LG2-EBV (open circles) in cytotoxicity assays. Error bars
represent 95% CI calculated from triplicates. (B) Interferon-g release by CD4
þ clones raised from WMMH donors. Clones APLD2, APLD3, APLD4 and
KPLD10 from donors AP and KP were used as effectors against targets consisting of recipient melanoma WMMH (solid dots), recipient-derived EBV-LCL
(EBV-MH; solid triangles) and the feeder cells LG2-EBV in a cytokine secretion assay. Error bars represent 95% CI calculated from triplicates. Results were
representative of at least two experiments.
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þ and CD8
þ clones, particularly the former, could be
generated from the blood of HLA-identical normal sibling donors
of melanoma sufferers. All previous reports of melanoma-reactive
cytotoxic cells raised from normal donors, including the only other
study using HLA-matched identical donors (Kurokawa et al, 2002),
have identified dominant MHC class I-restricted responses in
cultured cells. (Kurokawa et al, 2002; Glazyrin et al, 2003; Nolte
et al, 2003). Our report is the first to demonstrate the generation of
predominantly CD4
þ melanoma-reactive clones, many interferon-
g secreting, from normal donors.
We generated cell lines from biopsies of metastatic lesions of
two patients with melanoma. These lines had the morphological
and culture features of neoplastic cells and expressed antigens
typical of melanoma cells. Using PBL of HLA-identical siblings
as responder cells, melanoma-reactive effectors were isolated
from three HLA-identical siblings of the two melanoma cell line
originators. Clones were obtained from MLTCs with an overall
cloning efficiency of approximately 3%. Both CD4
þ and CD8
þ
clones were melanoma reactive, but CD4
þ clones dominated the
cultures. CD8
þ clones derived after cell sorting of bulk cultures
failed to persist for longer than 2 months in vitro. Despite this,
some CD8
þ clones efficiently lysed parental melanoma lines. In
cytokine release assays, CD8
þ clones released interferon-g but not
IL-4 (data not shown) in response to stimulation with melanoma
lines consistent with the acquisition of a Tc1 phenotype.
The reason for the dominance of CD4
þ clones and the failure to
propagate long-term CD8
þ clones from these cultures is unclear.
Possibilities include the specific antigen stimulus (Glazyrin et al,
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Figure 5 Characterisation of clone PR3. (A) Specific lysis by clone PR3
against an MAGE-3-transfected (closed squares) or a vector-only-
transfected (open squares) HLA-DR11þ EBV-transformed cell line. (B)
Interferon-g release by clone PR3. Interferon-g release by PR3 cells was
measured following culture with HLA-DR11  melanoma cells (ET-1,
Me18732), HLA DR11þ melanoma cells (GRA, MD, LB33, OI and
WMPG) and an HLA DR11þ EBV-transformed cell line either control-
transfected (EBV) or transfected with MAGE-3 (EBV-M3). Interferon-g
release by the stimulating cells was subtracted.
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Figure 6 Inhibition of APLD2 cytotoxicity and interferon- release. (A)
L243, W6/32, OKT3, anti-CD4 and anti-CD8 Abs were added to 4-h
51Cr-
release cytotoxicity assays using APLD2 as effector and WMMH as targets.
(B) The same Abs were also used to block overnight interferon- release by
APLD2 against WMMH. (C) To test the validity of the Ab preparations, the
Abs were used to block 5-day one-way mixed lymphocyte reactions using
PBMCs from random allogeneic normal donors. Cytotoxicity assays were
performed in triplicates, and error bars represent 95% CI of triplicates.
Percentage-specific lysis at an effector:target ratio of 50:1 is shown.
Dose–responses using lower effector:target ratios were observed and are
not shown. Interferon-g release assay was performed in duplicate and error
bars represent range of duplicates.
3H-thymidine incorporation assay to
measure lymphocyte proliferation was performed in quadruplicates and
error bars represent 95% CIs. All results representative of two
experiments.
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matching in this allogeneic system. Although the original experi-
ments cloning melanoma-reactive CD8
þ CTL were also performed
with whole autologous tumour cells (Herin et al, 1987), others have
also reported difficulty isolating CD8
þ CTL clones following this
type of stimulation (Takahashi et al, 1995). In one study that
generated tumour-specific CD8
þ cytotoxic T cells from allogeneic
donors, MLTCs were initiated with a highly purified population of
CD8
þ donor lymphocytes potentially underestimating the role
of CD4
þ clones in the immune response. (Dorrschuck et al, 2004).
Our data are the first to document the results of cloning MHC class
I and II HLA-matched allogeneic effector cells stimulated with
whole tumour cells and are in line with previous observations made
using autologous MLTC (Takahashi et al, 1995).
Approximately half of the CD4
þ clones were weakly cytotoxic
against the melanoma cell line used for stimulation. More than half
of the remaining noncytotoxic CD4
þ clones released interferon-g
on exposure to the melanoma line. Several other studies have
reported isolation of HLA class II-restricted melanoma-specific
CD4
þ CTLs, including clones recognising MAGE-3, NY-ESO1 and
tyrosinase epitopes (Kobayashi et al, 1998; Chaux et al, 1999;
Manici et al, 1999; Zarour et al, 2000). We isolated a CD4
þ HLA-
DR11-restricted clone directed against an MAGE-3 epitope from
one of our three normal donors. We found no evidence of class I
restriction in any CD4
þ clone as has been described previously
(LeMay et al, 1993; Mitchell et al, 1993; Darrow et al, 1996).
Restriction of MAGE epitopes via non-HLA-DR class II molecules
as described previously is a more likely explanation for our
findings (Schultz et al, 2000; Mandic et al, 2005). None of the
CD4
þ T-cell clones established in this study secreted interferon-g
in response to recipient-derived nonmelanoma cells. Similarly,
CD8
þ clones did not lyse normal cells of melanoma patients,
suggesting that sibling donor cells capable of mediating graft-
versus-host reactions did not dominate the cultures. Although in
most cases the target antigen could not be identified, the failure to
lyse normal patient cells suggested that melanoma-specific or
melanoma-associated rather than minor histocompatibility anti-
gens were common targets of clones isolated from normal donors.
Our data do not allow us to assess the use of HLA-identical
sibling donor lymphocytes as a starting population for the
generation of antimelanoma cells for adoptive therapy. Our
CD4
þ clones proliferated well, but we did not specifically address
the question of expansion to therapeutic numbers beyond 10
9 cells
in total. Further testing is needed before it can be determined
whether a sufficient number of melanoma-reactive cells can be
obtained for therapeutic purposes from HLA-identical donors of
melanoma sufferers. Nevertheless, our data allow us to conclude
that melanoma-reactive precursor cells exist in the peripheral
blood of such donors and that the precursors of melanoma-
reactive CD4
þ T cells are common. Although we cannot be certain
of the role of CD4
þ cells in mediating antimelanoma tumour
immunity, they may have a number of effects: direct antitumour
effector cells, provision of help to CD8
þ clones with greater direct
cytotoxic potential or assistance in the generation of lymphocytes
with long-lived memory. They have beneficial therapeutic effects in
animal models even when not directly lytic in vitro (Kahn et al,
1991; Shinomiya et al, 1995). If, as described in cytomegalovirus
infection (Gamadia et al, 2003), the presence of interferon-g-
secreting CD4
þ cells is essential for the development of mature
and effective CD8 and B-cell responses, infusion of an mixed
population of melanoma-reactive cells of both CD4
þ and CD8
þ
phenotype may assist CD8
þ-cell survival and maturation and
result in enhancement of a broad antimelanoma immune response.
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